KRT19 and thyroid gland papillary carcinoma: Sahoo et al, reported that 25% of their follicular adenomas had extensive immunoreactivity for CK19, and Miettinen et al also reported that 59% of their follicular carcinomas showed CK19 reactivity in more than 10% of the lesions, suggesting that CK19 expression patterns are not reliable for the distinction between papillary carcinomas and follicular neoplasms [5].